nccRCC

Efficacy of Durvalumab Plus Savolitinib in MET-Driven Papillary Renal Cancer: Insights From CALYPSO
At the American Society of Clinical Oncology 2025 Genitourinary Cancers Symposium, the final efficacy analysis of the phase II CALYPSO study was presented along with a new ctDNA analysis from the study. Previous data from the phase II CALYPSO study has demonstrated the efficacy of durvalumab in combination with MET inhibitor savolitinib in patients with MET-driven advanced papillary renal cancer (aPRC), leading to the ongoing phase III SAMETA study. ...
Advertisement
Advertisement

RCC Knowledge Hubs

Renal Cell Carcinoma
Renal Cell Carcinoma

Conference Coverage

Advertisement
Advertisement
Latest News